Cereno Scientific signs CRO for Phase II study with drug candidate CS1 in rare disease PAH
Cereno Scientific today announced that the company has signed a letter of intent with the global contract research organization (CRO) Worldwide Clinical Trials . Worldwide will provide support and guidance in the final preparatory steps as well as conduct the clinical Phase II study with drug candidate CS1 in pulmonary arterial hypertension (PAH). The clinical trial application process for the study has been initiated and the study start is expected to be